The AVITHRAPID consortium "Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases" is part of the Horizon Europe Framework Programme and consists of 18 participants and partners from 8 countries.
Project
Description
Outcome &
Deliverables
Research
Repositories
Latest News & Events from AVITHRAPID
AVITHRAPID in Berlin
On 16 and 17 of June, members of our consortium from across Europe came together for a dedicated two-day general meeting focused on shaping the future of antiviral development. This exclusive meeting was designed to foster strategic dialogue, operational alignment, and scientific
AVITHRAPID Seminar Series: Advancing European Collaboration on Broad-Spectrum Antivirals
On May 19, 2025, AVITHRAPID held the second event in its official seminar series, strengthening ties with a key Horizon Europe sibling initiative: the NAVIPP Consortium (New Antivirals Against Infections with Pandemic Potential). This encounter reflects a shared vision—to accelerate the discovery
Halicin: A Dual-Action Molecule Against COVID-19 – New Findings from AVITHRAPID
AVITHRAPID scientists uncover how a repurposed antibiotic disrupts the core of the coronavirus replication machinery – opening new doors for broad-spectrum antiviral development. A Strategic Target: The Viral Protease 3CLpro SARS-CoV-2, the virus behind COVID-19, uses a specific enzyme, the 3C-like protease